1. Scrip
  2. >>Digital Technologies
  3. >>AI

Korean Biopharma Catching Up On AI, But What Are The Challenges?

In-House Platforms Plus Collaborations

 
• By Jung Won Shin

While South Korea's biopharma sector has made progress in its digital transformation, including the adoption of AI technologies, a recent report has identified multiple remaining challenges.

marathon runners
Digital Transformation Becoming Indispensable Factor To Buoy Global Competitiveness (Shutterstock)

The South Korean biopharma industry is actively adopting AI technology for digital transformation, although experts note that its technology level is still relatively weak compared with major global countries.

While various areas of new drug development are being digitalized, AI-driven new drug candidates can serve a crucial role in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from AI

How To ‘Shift Left’ With Agentic AI, Balance Compliance And Creativity In MLR Reviews

 
• By Vibha Ravi

Experts from UCB, Alnylam, Lantheus and Medtronic deliberated at a recent summit best uses of agentic AI in the MLR review process, its human replaceability quotient and ways to balance creativity with compliance, a significant discussion amid DTC advertising and US FDA scrutiny.

Galien Forum Notebook: AI, Pharma Groupthink Take Center Stage

 
• By Alaric DeArment

At the annual biopharma confab, biopharma execs shared their thoughts about where artificial intelligence is heading and pharma avoiding following the leader in hot areas.

Lilly Takes Big Step Forward In AI With NVIDIA Partnership

 
• By Alaric DeArment

The drugmaker announced it would work with the tech giant to deploy a supercomputer that it will use to train AI models and enhance drug discovery, development and manufacturing.

Biopharma Has Been Fast To Adopt AI/ML, But It’s Unclear How It Will Play Out

 
• By Alaric DeArment

One panelist at the BioFuture conference said AI is a bubble, but that when the bubble bursts it will leave a lot of innovation in its wake.

More from Digital Technologies

BioFuture Notebook: State Of Industry Seen As ‘Bewildering,’ ‘Confusing’ And ‘Uncertain’

 
• By Alaric DeArment

Speakers at the BioFuture conference discussed how confusing the policy environment has become, skepticism about AI/ML in drug development, the future of cancer immunotherapy, ideas for accelerating rare disease therapies and where the biopharma financing market is going.

Takeda APAC Head On ‘Conscious’ Pricing, Qdenga And Reverse Digital Mentoring

 
• By Anju Ghangurde

Takeda's APAC chief talks about driving affordability and access for products like Adcetris and Qdenga, focusing on the region's diverse needs. “Watch this space” he said on the Japanese group’s Innovation Capability Centers, as they shape digital solutions to transform operations.

Lilly Provides AI/ML Modeling To Smaller Firms Via New Platform

 
• By Alaric DeArment

The drugmaker launched TuneLab, part of Catalyze360, which gives partners access to its artificial intelligence/machine learning drug discovery model trained on its research data.